Historically, Risperdal was first approved by the U.S. Food and Drug Administration (FDA) in 1993 for use in patients with manic episodes or mixed delusional episodes as patients with schizophrenia. In 2007, the FDA approved the use of this drug for treatment for bipolar disorder and schizophrenia for children and teenagers.
In addition to Gynecomastia, Risperdal has been associated with tardive dyskinesia, which is a muscle and movement disorder that may lead to uncontrolled movements of the limbs and face.
In addition, there have been reports that Risperdal has in rare cases caused increased heart rate, breathing problems, muscle stiffness, weakness, fatigue, seizures and loss of bladder control. You may also take the expert advice from Risperdal gynecomastia attorneys to solve your legal issues.
Many of the lawsuits filed in the mass tort cases claimed that Risperdal caused male patients to develop breasts. This condition is known as Gynecomastia.
In some cases, men have needed mastectomies or liposuction to remove the breast tissue. The emotional effects of this condition are severe. Many of the patients who have suffered because of the Risperdal drug use are suffering emotional and mental illnesses.
The U.S. Justice Department reached a settlement with Johnson & Johnson, which is the maker of Risperdal. The settlement of $2.2 billion and a misdemeanor plea comes after a long investigation into the marketing of the pharmaceutical product, Risperdal. It is an anti-psychotic drug known to deliver harmful side effects, especially to young boys and young men most often prescribed the medicine.